The global community is well aware of the devastatinTop Generalizable Antivirals for Stockpiling in Emergencies: A Review and Gap Analysis
The global community is well aware of the devastating potential of viral outbreaks. From the ongoing challenges posed by seasonal flu to the devastation caused by the COVID-19 pandemic, the need for effective antiviral therapies is clear. While vaccines and public health measures can help to reduce some risks, antiviral drugs remain a powerful tool for treating viral infections once they occur (Andrei, 2021). Given the unpredictable nature of viral threats, it is critical to consider which antivirals are most generalizable to a wide range of viral pathogens and which treatment gaps still need to be filled (Groaz, 2021).
1. Remdesivir: Broad-Spectrum Activity Against RNA Viruses
Remdesivir (brand name Veklury), which was initially developed to treat Ebola, has emerged as an important antiviral agent in the fight against RNA viruses (Warren, 2016). It inhibits viral RNA-dependent RNA polymerase, an enzyme required for viral replication. Remdesivir is effective against several coronaviruses, including SARS-CoV-2, and was approved for emergency use during the COVID-19 pandemic (Beigel, 2020).
Remdesivir has been tested and approved for COVID-19, but it has also shown promise against a variety of other RNA viruses. Its effectiveness against other viral infections, such as Zika, hepatitis C, and even certain strains of influenza, is being studied (Radoshitzky, 2023).
Remdesivir's limitations in treating certain viral infections, such as its relatively narrow efficacy window and intravenous administration requirement, make it difficult to use in an emergency (Piscoya, 2020). This limitation highlights the need for further optimization in terms of oral bioavailability and broad antiviral activity across multiple viral families.
2. Favipiravir: Effective Against Multiple RNA Viruses
Favipiravir (Avigan), an antiviral medication originally developed for influenza, has been shown to be effective against a variety of RNA viruses, including Ebola, Zika, and SARS-CoV-2 (Marlin, 2022). Favipiravir inhibits viral RNA polymerase, which prevents virus replication (Shiraki, 2020). It is particularly appealing for stockpiling due to its demonstrated efficacy in treating viral infections such as influenza and its ability to be repurposed for novel viruses.
The drug has been used successfully in a variety of emergency situations, including in Japan during the COVID-19 outbreak, but its effectiveness is still debated (Cao, 2020). While it shows promise in reducing the severity and duration of illness in influenza patients, further clinical trials are needed to fully establish its role against other viral pathogens (Shiraki, 2020).
Favipiravir is typically administered orally, which makes it more suitable for stockpiling compared to intravenous alternatives (Bielicki, 2020). However, the drug's side effects, such as teratogenicity (causing birth defects), and its limited efficacy in some viral infections, suggest that additional antiviral therapies will still be required to fill in the gaps (Sangawa, 2013).
3. Molnupiravir: An Oral Option for RNA Viruses
Molnupiravir, like remdesivir and favipiravir, targets the RNA-dependent RNA polymerase enzyme, causing viral mutations that inhibit replication (FDA, 2021). Molnupiravir is particularly appealing due to its oral administration, which makes it far easier to stockpile and distribute than intravenous treatments (ASHP, 2023).
Molnupiravir has been shown to reduce the severity of COVID-19 and shorten recovery time, especially in patients who have mild to moderate symptoms (Sun, 2023). Its broad activity against other RNA viruses, such as influenza and RSV (respiratory syncytial virus), suggests that it could be a useful tool for managing future viral outbre...
(All Rights Reserved)